Hantavirus Diagnostics: RT-PCR vs. Serology Complicate MV Hondius Andes Response
Testing methodologies present ongoing challenges for accurate and timely hantavirus detection among passengers and crew from the MV Hondius Andes, with implications for regional diagnostic capacity and outbreak management.
Diagnostic Hurdles Impact Hantavirus Outbreak Management
PRAIA, CAPE VERDE – The Hantavirus Cruise outbreak, originating on the MV Hondius Andes in May 2026, continues to highlight critical diagnostic challenges, particularly on the appropriate use and interpretation of RT-PCR and serology tests. As the response efforts mature, understanding the nuances of these testing methods is paramount for accurate case identification, contact tracing, and public health interventions.
RT-PCR: Early Detection, Limited Window
Real-time reverse transcription polymerase chain reaction (RT-PCR) remains the gold standard for detecting acute hantavirus infection. This molecular test identifies viral genetic material, offering the earliest possible detection in symptomatic individuals. But, the utility of RT-PCR is time-sensitive; viral loads typically peak and then decline as the immune response mounts, meaning the test is most effective in the initial phase of illness, often within the first week of symptom onset. For individuals with a longer symptom duration or those tested later in their clinical course, RT-PCR may yield false-negative results, even in the presence of active infection. This narrow detection window poses a bigly challenge in an evolving outbreak, especially when initial symptoms might be non-specific, delaying presentation for testing.
Serology: The Broader Picture, Delayed Confirmation
Serological assays, which detect antibodies (IgM and IgG) produced by the body in response to the virus, provide a broader diagnostic window. IgM antibodies typically become detectable within a few days to a week after symptom onset and can persist for several weeks or months, indicating a recent infection. IgG antibodies usually appear later than IgM though can remain detectable for years, signifying past exposure or immunity. While serology can confirm infections missed by RT-PCR due to timing, it has its own limitations. The initial delay in antibody production means serological tests may be negative in the very early stages of infection, leading to potential false negatives during the hyperacute phase. And, the persistence of IgM antibodies can make it difficult to differentiate between a new, acute infection and a resolving or subacute infection, particularly in areas with endemic hantavirus circulation or previous exposure among the population.
Cross-Reactivity Concerns
A critical issue complicating serological diagnosis is the potential for cross-reactivity. Hantaviruses are a diverse group, and antibodies against one hantavirus species can sometimes react with antigens from other, related hantaviruses. This phenomenon can lead to false-positive results, making it difficult to definitively identify the specific hantavirus responsible for the outbreak without more sophisticated confirmatory tests like neutralization assays or sequencing. While the primary hantavirus strain associated with the MV Hondius Andes outbreak is being characterized, the potential for cross-reactivity with other hantaviruses known to circulate in rodent populations in West Africa could impact diagnostic precision, as noted by some public health agencies.
West African Laboratory Capacity
The diagnostic strategy for the MV Hondius Andes outbreak has also highlighted regional laboratory capacity concerns. While certain national reference laboratories in West Africa possess molecular diagnostics capabilities for many viral pathogens, the infrastructure and trained personnel specifically for hantavirus testing, particularly advanced serological differentiation and sequencing, vary. Before the MV Hondius Andes event, hantavirus was not a commonly prioritized pathogen for widespread routine surveillance or diagnostic investment in a number of parts of the region. International partnerships and surge support have been crucial in expanding testing capabilities, including the deployment of mobile laboratories and expert teams. But, sustaining strong diagnostic infrastructure for emerging pathogens like hantavirus requires long-term investment in equipment, reagents, biosafety measures, and continuous staff training across the region. As of late September 2026, efforts continue to strengthen diagnostic networks and ensure timely, accurate results for all affected individuals and to inform broader public health surveillance strategies in Cape Verde and neighboring countries.
